Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – OncologyPipeline Leads with Most Promising Mo...
3.1.1 Overview3.1.2 Opportunity and Unmet Need3.1.3 Strategic Pipeline Assessment3.1.4 Comparative Analysis of Late Stage ...
6.1.3 Strategic Pipeline Assessment6.1.4 Comparative Analysis Based on Major Characteristics6.1.5 Promising Drugs under Cl...
10.1.4 Comparative Analysis Based on Major Characteristics10.1.5 Promising Drugs under Clinical Development11 Comparative ...
Table 8: Comparative Analysis of Late Stage Pipeline Molecules in Rheumatoid Arthritis,Based on Major CharacteristicsTable...
Figure 30: Comparative Analysis of Late Stage Pipeline Molecules in   Major Indications, byPhase, 2011Figure 31: Comparati...
Upcoming SlideShare
Loading in...5
×

ReportsnReports – Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development

229

Published on

GBI Research, a leading business intelligence provider, has released its latest research “Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development”, which provides insights into the unmet needs targeted by late stage pipeline molecules across major therapy areas. The report examines the safety, efficacy parameters of molecules in development. The report includes insights into the R&D pipeline various therapy areas and identifies potential blockbusters.

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
229
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

ReportsnReports – Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development

  1. 1. Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – OncologyPipeline Leads with Most Promising Molecules in Late Stage DevelopmentGBI Research, a leading business intelligence provider, has released its latest research“Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – OncologyPipeline Leads with Most Promising Molecules in Late Stage Development”, which providesinsights into the unmet needs targeted by late stage pipeline molecules across majortherapy areas. The report examines the safety, efficacy parameters of molecules indevelopment. The report includes insights into the R&D pipeline various therapy areas andidentifies potential blockbusters.Buy Now: Late Stage Pipeline Molecules in Major Indications MarketBrowse All: Latest Market Research ReportsIn-depth analysis of the report is based on propriety databases, primary and secondaryresearch and in-house analysis by GBI Research’s team of experts.ScopeProfiles of promising late stage pipeline molecules across various therapy areasAnalysis of safety, efficacy, mechanism of actions of major pipeline drugs targeted at majortherapy areasComparison of late stage drugs based on safety, efficacy, mechanism of action, unmet needtargeted and stage of disease targetedReasons to buyBuild effective strategies to launch their pipeline products by identifying geographies withhigh potential for growth.Exploit in-licensing and out-licensing opportunities by identifying products that might filltheir portfolio gaps.Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.Table of Contents1 Table of Contents1.1 List of Tables1.2 List of Figures2 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Introduction2.1 GBI Research Report Guidance3 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Oncology3.1 Comparative Analysis of Late Stage Pipeline Molecules in NSCLC
  2. 2. 3.1.1 Overview3.1.2 Opportunity and Unmet Need3.1.3 Strategic Pipeline Assessment3.1.4 Comparative Analysis of Late Stage Pipeline Molecules Based on Major Characteristics3.1.5 Promising Drugs under Clinical Development3.1.6 Other Promising Drugs under Clinical Development3.2 Comparative Analysis of Late Stage Pipeline Molecules in Colorectal Cancer3.2.1 Overview3.2.2 Opportunity and Unmet Need3.2.3 Strategic Pipeline Assessment3.2.4 Trends in Colorectal Cancer Pipeline3.2.5 Comparative Analysis Based on Major Characteristics3.2.6 Promising Drugs Under Clinical Development3.3 Comparative Analysis of Late Stage Pipeline Molecules in Breast Cancer3.3.1 Overview3.3.2 Opportunity and Unmet Need3.3.3 Strategic Pipeline Assessment3.3.4 Comparative Analysis Based on Major Characteristics3.3.5 Promising Drugs under Clinical Development3.4 Comparative Analysis of Late Stage Pipeline Molecules in Prostate Cancer3.4.1 Overview3.4.2 Opportunity and Unmet Need3.4.3 Strategic Pipeline Assessment3.4.4 Trends in Prostate Cancer Pipeline3.4.5 Comparative Analysis Based on Major Characteristics3.4.6 Promising Drugs under Clinical Development4 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Metabolic Disorders4.1 Comparative Analysis of Late Stage Pipeline Molecules in Type II Diabetes4.1.1 Overview4.1.2 Opportunity and Unmet Need4.1.3 Strategic Pipeline Assessment4.1.4 Comparative Analysis Based on Major Characteristics4.1.5 Promising Drugs under Clinical Development5 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Respiratory Diseases5.1 Comparative Analysis of Late Stage Pipeline Molecules in COPD5.1.1 Overview5.1.2 Opportunity and Unmet Need5.1.3 Strategic Pipeline Assessment5.1.4 Comparative Analysis Based on Major Characteristics5.1.5 Promising Drugs under Clinical Development6 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Musculoskeletal6.1 Comparative Analysis of Late Stage Pipeline Molecules in Rheumatoid Arthritis6.1.1 Overview6.1.2 Opportunity and Unmet Need
  3. 3. 6.1.3 Strategic Pipeline Assessment6.1.4 Comparative Analysis Based on Major Characteristics6.1.5 Promising Drugs under Clinical Development7 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Central Nervous System7.1 Comparative Analysis of Late Stage Pipeline Molecules in Epilepsy7.1.1 Overview7.1.2 Opportunity and Unmet Need7.1.3 Strategic Pipeline Assessment7.1.4 Comparative Analysis Based on Major Characteristics7.1.5 Promising Drugs under Clinical Development7.2 Comparative Analysis of Late Stage Pipeline Molecules in Multiple Sclerosis7.2.1 Overview7.2.2 Opportunity and Unmet Need7.2.3 Strategic Pipeline Assessment7.2.4 Comparative Analysis Based on Major Characteristics7.2.5 Promising Drugs under Clinical Development7.3 Comparative Analysis of Late Stage Pipeline Molecules in Major Depressive Disorder7.3.1 Overview7.3.2 Opportunity and Unmet Need7.3.3 Strategic Pipeline Assessment7.3.4 Comparative Analysis Based on Major Characteristics7.3.5 Promising Drugs under Clinical Development8 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Immunology8.1 Comparative Analysis of Late Stage Pipeline Molecules in Crohn’s Disease8.1.1 Overview8.1.2 Opportunity and Unmet Need8.1.3 Strategic Pipeline Assessment8.1.4 Comparative Analysis Based on Major Characteristics8.1.5 Promising Drugs under Clinical Development9 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Cardiovascular9.1 Comparative Analysis of Late Stage Pipeline Molecules in Hypertension9.1.1 Overview9.1.2 Opportunity and Unmet Need9.1.3 Strategic Pipeline Assessment9.1.4 Comparative Analysis Based on Major Characteristics9.1.5 Promising Drugs under Clinical Development10 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Infectious Disease10.1 Comparative Analysis of Late Stage Pipeline Molecules in HIV/ AIDS10.1.1 Overview10.1.2 Opportunity and Unmet Need10.1.3 Strategic Pipeline Assessment
  4. 4. 10.1.4 Comparative Analysis Based on Major Characteristics10.1.5 Promising Drugs under Clinical Development11 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Gastrointestinal Diseases11.1 Comparative Analysis of Late Stage Pipeline Molecules in Ulcerative Colitis11.1.1 Overview11.1.2 Opportunity and Unmet Need11.1.3 Strategic Pipeline Assessment11.1.4 Comparative Analysis Based on Major Characteristics11.1.5 Promising Drugs under Clinical Development12 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Conclusion12.1 Oncology Pipeline Holds Most Prominence for Market Players12.2 Colorectal Cancer Most Noteworthy Indications With Respect To Phase III Activity12.3 An Average Of 50% Unmet Need Common in Oncology Therapeutics Followed By RA12.4 Kinase Inhibitors – Most Important First-In-class Drug12.5 Receptor Tyrosine Kinase and Vaccines Are Major Promising Class Based On SalesForecast for Oncology13 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –Appendix13.1 Marketed Definitions13.2 Abbreviations13.3 Research Methodology13.3.1 Coverage13.3.2 Secondary Research13.3.3 Primary Research13.3.4 Expert Panel Validation13.4 Contact Us13.5 Disclaimer13.6 SourcesList of TablesTable 1: Comparative Analysis of Late Stage Pipeline Molecules in NSCLC, Based on MajorCharacteristicsTable 2: Comparative Analysis of Late Stage Pipeline Molecules in NSCLC, Other PromisingCandidates in Late Stage Pipeline, 2011Table 3: Comparative Analysis of Late Stage Pipeline Molecules in Colorectal Cancer, Basedon Major CharacteristicsTable 4: Comparative Analysis of Late Stage Pipeline Molecules in Breast Cancer, Based onMajor CharacteristicsTable 5: Comparative Analysis of Late Stage Pipeline Molecules in Prostate Cancer, Based onMajor CharacteristicsTable 6: Comparative Analysis of Late Stage Pipeline Molecules in Type 2 Diabetes, Basedon Major CharacteristicsTable 7: Comparative Analysis of Late Stage Pipeline Molecules in COPD, Based on MajorCharacteristics
  5. 5. Table 8: Comparative Analysis of Late Stage Pipeline Molecules in Rheumatoid Arthritis,Based on Major CharacteristicsTable 9: Comparative Analysis of Late Stage Pipeline Molecules in Epilepsy, Based on MajorCharacteristicsTable 10: Comparative Analysis of Late Stage Pipeline Molecules in Multiple Sclerosis, Basedon Major CharacteristicsTable 11: Comparative Analysis of Late Stage Pipeline Molecules in Major DepressiveDisorder, Based on Major CharacteristicsTable 12: Comparative Analysis of Late Stage Pipeline Molecules in Crohn’s Disease, Basedon Major CharacteristicsTable 13: Comparative Analysis of Late Stage Pipeline Molecules in Hypertension, Based onMajor CharacteristicsTable 14: Comparative Analysis of Late Stage Pipeline Molecules in HIV/AIDS, Based onMajor CharacteristicsTable 15: Comparative Analysis of Late Stage Pipeline Molecules in Ulcerative Colitis, Basedon Major CharacteristicsList of FiguresFigure 1: NSCLC Pipeline, Global, Mechanism of Action, 2010Figure 2: NSCLC Pipeline, Global, Technology Analytics Framework, 2010Figure 3: Colorectal Cancer Pipeline, Global, Mechanism of Action, 2010Figure 4: Colorectal Cancer Pipeline, Global, Technology Trends Analytic Framework, 2010Figure 5: Breast Cancer Pipeline, Global, Mechanism of Action, 2010Figure 6: Breast Cancer Pipeline, Global, Technology Trends Analytic Framework, 2010Figure 7: Prostate Cancer Pipeline, Global, Mechanism of Action, 2010Figure 8: Prostate Cancer Pipeline, Global, Technology Trends Analytic Framework, 2010Figure 9: Type 2 Diabetes Pipeline, Global, Mechanism of Action, 2010Figure 10: Type 2 Diabetes Pipeline, Global, Technology Trends Analytic Framework, 2010Figure 11: COPD Pipeline, Global, Mechanism of Action, 2010Figure 12: COPD Pipeline, Global, Technology Trends Analytic Framework, 2010Figure 13: Rheumatoid Arthritis Pipeline, Global, Mechanism of Action, 2010Figure 14: Rheumatoid Arthritis Pipeline, Global, Technology Trends Analytic Framework,2010Figure 15: Epilepsy Pipeline, Global, Mechanism of Action, 2010Figure 16: Epilepsy Pipeline, Global, Technology Trends Analytic Framework, 2010Figure 17: Multiple Sclerosis Pipeline, Global, Mechanism of Action, 2010Figure 18: Multiple Sclerosis Pipeline, Global, Technology Trends Analytic Framework, 2009Figure 19: Major Depressive Disorder Pipeline, Global, Mechanism of Action, 2010Figure 20: Major Depressive Disorder Pipeline, Technology Trends Analytic Framework, 2011Figure 21: Crohn’s Disease Pipeline, Global, Mechanism of Action, 2010Figure 22: Crohn’s Disease Pipeline, Global, Technology Trends Analytic Framework, 2010Figure 23: Anti-hypertension Pipeline, Global, Mechanism of Action, 2010Figure 24: Anti Hypertension Pipeline, Global, Technology Trends Analytic Framework, 2010Figure 25: HIV/AIDS Pipeline, Global, Mechanism of Action, 2010Figure 26: HIV/ AIDS Pipeline, Global, Technology Trends Analytic Framework, 2010Figure 27: Ulcerative Colitis Pipeline, Global, Mechanism of Action, 2010Figure 28: Ulcerative Colitis Pipeline, Global, Technology Trends Analytic Framework, 2009Figure 29: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, byTherapy Area, 2011
  6. 6. Figure 30: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, byPhase, 2011Figure 31: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications,Unmet Needs in % and $m, 2009Figure 32: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications,Technology Trends, 2011Figure 33: Comparative Analysis of Late Stage Pipeline Molecules in Major Indications, SalesForecast of Some Key Late Stage Pipeline Drugs in Oncology, ($m), 2017Latest Market Research Reports:Middle East and Africa (MEA) System Integration (SI) Services Market Analysis and Forecast(2011-2016)Food Shopper Insights: Grocery Shopping Trends in the U.S.Hotel Foodservice Trends in the U.S.Natural and Organic Foods and Beverages in the U.S., 3rd EditionTrends in U.S. Foodservice ContractingUnderbanked and Unbanked Consumers in the U.S.: Successfully Targeting Consumers ofAlternative Financial ServicesThin Film Solar PV Manufacturing Equipment WorldwideDrugs of Abuse Testing MarketsAbout Us:ReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr. Priyank7557 Rambler road,Suite 727, Dallas, TX 75231Tel: +1-888-989-8004 EXT 106E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comBlog: http://www.reportsnreportsblog.com

×